SCHEMBL2934840

SCHEMBL2934840

COc1c(F)c(F)c(-c2c3ccccc3c(-c3c(F)c(F)c(F)c(F)c3F)c3c(F)c(F)c(F)c(F)c23)c(F)c1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.45
KDM4E B2RXH2 6/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MAPK1 P28482 1/20 0.45
POLB P06746 3/20 0.37
HSD17B10 Q99714 1/20 0.37
BUB1 O43683 1/20 0.34
CYP2C9 P11712 3/20 0.33
CYP1A2 P05177 3/20 0.33
MAPT P10636 2/20 0.33
CYP2C19 P33261 2/20 0.33
HPGD P15428 2/20 0.33
NPC1 O15118 2/20 0.33
CYP3A4 P08684 1/20 0.33
RAB9A P51151 1/20 0.33
NPSR1 Q6W5P4 2/20 0.32
GAA P10253 1/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2724358 1.00 ALDH1A1 (0.45) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB
SCHEMBL2726926 0.92 KDM4E (0.38) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB
SCHEMBL2726486 0.92 PDE4B (0.41) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB
SCHEMBL2710337 0.90 ALDH1A1 (0.50) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB
SCHEMBL2727925 0.89 ALDH1A1 (0.42) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB
SCHEMBL2726358 0.89 SMN1; SMN2 (0.36) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB
SCHEMBL2731612 0.88 KDM4E (0.52) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB
SCHEMBL2727154 0.88 ACHE (0.43) ALDH1A1KDM4ESMN1; SMN2MAPK1
SCHEMBL2726648 0.88 KDM4E (0.35) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB
SCHEMBL2709488 0.88 KDM4E (0.35) ALDH1A1KDM4ESMN1; SMN2MAPK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2445987-B1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS CYALUME TECH INC (US) 2018-05-02 EP disclosed
EP-2445987-B1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS CYALUME TECH INC (US) 2018-05-02 EP disclosed
US-8257620-B2 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. (US) 2012-09-04 US disclosed
US-8257620-B2 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. (US) 2012-09-04 US disclosed
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. 2010-12-30 US disclosed
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYP2F1, FLAD1, AFF1 ALDH1A1 34/4885KDM4E 670/4885SMN1; SMN2 4856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.